Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of complement in the immunopathogenesis of acetylcholine receptor antibody-positive generalized myasthenia gravis: bystander or key player?

15 Apr 2025

Abstract excerpt

The complement system is a key component of the innate immune system. In antiacetylcholine receptor (AChR) antibody-positive (Ab+) generalized myasthenia gravis (MG), complement activation has long been considered a principal driver of pathology. Understanding the role of complement in AChR-Ab+ generalized MG has gained increasing importance in recent years, as anticomplement drugs have been approved for clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal resistance and susceptibility
Share to Myasthenia Gravis and Thymoma
Share to Peripheral Neuropathies and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40303417
DOI: 10.3389/fimmu.2025.1526317

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of complement in the immunopathogenesis of acetylcholine receptor antibody-positive generalized myasthenia gravis: bystander or key player?PMID 40303417Read ↗

Complement and myasthenia gravisSemantic proximity Read ↗

Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief reviewSemantic proximity Read ↗

Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)Semantic proximity Read ↗

Distribution and Temporal Changes of Autoantibody-Mediated Pathogenic Mechanisms Among Acetylcholine Receptor-Positive Myasthenia Gravis PatientsSemantic proximity Read ↗

Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.Semantic proximity Read ↗

Heterogeneity of acetylcholine receptor autoantibody-mediated complement activity in patients with myasthenia gravisSemantic proximity Read ↗

Complement Therapeutics in Autoimmune DiseaseSemantic proximity Read ↗

Pathogenesis of myasthenia gravis: update on disease types, models, and mechanismsSemantic proximity Read ↗

Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificitiesSemantic proximity Read ↗

Targeting complement in neurodegeneration: challenges, risks, and strategiesSemantic proximity Read ↗

Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement systemSemantic proximity Read ↗

Complement therapeutics in neurodegenerative diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.